Zacks Rating on Puma Biotechnology Inc (PBYI)

Puma Biotechnology Inc (PBYI) : The consensus on Puma Biotechnology Inc (PBYI) based on 5 analyst recommendation on the company stock is 2.2, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Puma Biotechnology Inc (PBYI) stock is expected to deviate a maximum of $17.47 from the average target price of $55.33 for the short term period. 3 Street Experts have initiated coverage on the stock with the most promising target being $70 and the most muted being $36.


Shares of Puma Biotechnology, Inc. rose by 17.42% in the last five trading days and 36.3% for the last 4 weeks. Puma Biotechnology, Inc. is up 73.63% in the last 3-month period. Year-to-Date the stock performance stands at -27.78%. Puma Biotechnology Inc (NYSE:PBYI): stock turned positive on Tuesday. Though the stock opened at $55.45, the bulls momentum made the stock top out at $57.209 level for the day. The stock recorded a low of $55 and closed the trading day at $56.62, in the green by 3.60%. The total traded volume for the day was 823,933. The stock had closed at $54.65 in the previous days trading.

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.